Stryker Sustainability Solutions is recalling more than 8,000 reprocessed medical devices. This is a Class II recall, according to the FDA, and these devices should no longer be used to treat patients.
“According to widespread reports from the breast imaging community, these shortages are creating immediate and substantial challenges for breast imaging practices nationwide," ACR warned the FDA in a letter May 11.
Meanwhile, the Maryland State Medical Society is formally urging the administration to reject the mid-year request, contending it will harm patients and providers.
John S. Scales, MD, a vascular and interventional specialist with Radiology Associates of Ocala in central Florida, has agreed to the terms, according to the state.
The Patients Before Monopolies Act was introduced into both the U.S. Senate and House of Representatives with bipartisan support. If it passes, pharmacy benefit managers would be required to divest from retail stores.
A woman in Texas alleges a U.S. Marine slipped abortion pills into her hot chocolate, resulting in the death of her fetus. She is suing the man, along with Aid Access—a nonprofit that provides nationwide access to abortion pills via telehealth.
Heartflow has officially gone public after selling more than 19 million shares of common stock during an upsized IPO. The California medtech company, known for its AI-powered CCTA evaluations, is now being traded on Nasdaq under the symbol HTFL.
Multiple lots of Draeger SafeStar and TwinStar filters—which are typically used during mechanical ventilation—are being removed from where they’re used and sold due to erroneous carbon dioxide readings.
Stryker Sustainability Solutions is recalling more than 8,000 reprocessed medical devices. This is a Class II recall, according to the FDA, and these devices should no longer be used to treat patients.
“According to widespread reports from the breast imaging community, these shortages are creating immediate and substantial challenges for breast imaging practices nationwide," ACR warned the FDA in a letter May 11.
Meanwhile, the Maryland State Medical Society is formally urging the administration to reject the mid-year request, contending it will harm patients and providers.
